Mardi Gomberg-Maitland, MD, MSc & Marc Humbert, MD, PhD will focus on several important aspects of PAH management including a discussion of clinical trial data on emerging therapeutics for the management of PAH; and a review of strategies to optimize outcomes for patients with PAH
Launch Date: December 15, 2021
Release Date: December 10, 2021
Expiration Date: November 30, 2022
This activity is intended for physicians, physician assistants, nurse practitioners, registered nurses, and pharmacists who activity manage/treat patients with pulmonary arterial hypertension.
Upon completion of this enduring material, participants should be able to:
In support of improving patient care, Rush University Medical Center is jointly accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for the healthcare team.
Rush University Medical Center designates this live activity for a maximum of AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ANCC Credit Designation – Nurses
The maximum number of hours awarded for this CE activity is contact hours.
Rush University Medical Center designates this knowledge-based CPE activity () for contact hours for pharmacists.
Participation in the entire knowledge-based activity is required to obtain a certificate. This activity is being presented without bias and with commercial support.
In accordance with the ACCME Standards for Commercial Support of CME, the Rush University Medical Center and Practice Point Communications will implement mechanisms, prior to the planning and implementation of this CME/CE activity, to identify and resolve conflicts of interest for all individuals in a position to control content of this CME/CE activity.
All planners and faculty participating in continuing education activities provided by the Rush University Medical Center are expected to disclose to the audience any support or relationship(s) with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. A commercial interest is any entity producing, marketing, re-selling, or distributing healthcare goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations. In addition, all faculty are expected to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in their presentation. The planners and faculty have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the Rush University Medical Center.
The following indicates the disclosure declaration information and the nature of those commercial relationships.
The speakers and planning committee members listed below have stated they have no significant relationships to disclose.
Sally Lemke, DNP, WHNP-BC
The following speakers and/or planners have stated that they have the following financial relationship(s) and they have agreed to see that all information they planned and/or present is done so fairly and without bias:
Mardi Gomberg-Maitland, MD, MSc
Consultant: Actelion/Janssen, Acceleron, Altavant, Reata, Gilead, United Therapeutics
Research Grants: Acceleron, Bayer, Altavant, and United Therapeutics to GW MFA
Marc Humbert, MD, PhD
Consultant: Acceleron, Bayer, Janssen, Merck, United Therapeutics
Research Grants: Acceleron, Janssen, Merck
Aaron Waxman, MD, PhD
Research Grants/Investigator: Acceleron Pharma, Gossamer Pharm
Advisory Committee/Board: United Therapeutics, ARIA CV, Gossamer Pharm, Acceleron Pharma
The Rush University Medical Center and Practice Point Communications present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The Rush University Medical Center and Practice Point Communications assume no liability for the information herein.
The Rush University Medical Center and Practice Point Communications protect the privacy of personal and other information regarding participants and educational collaborators. The Rush University Medical Center and Practice Point Communications will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME, ANCC, or ACPE.
Rush University Medical Center and Practice Point Communications maintain physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.
Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software (“Materials”) found on the site subject to the following terms, conditions, and exceptions:
The Materials are to be used solely for personal, noncommercial, informational, and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
Materials may not be published, uploaded, posted, or transmitted (other than as set forth herein) without prior written permission.